-
公开(公告)号：US20100210654A1
公开(公告)日：2010-08-19
申请号：US12530228
申请日：2008-03-07
申请人： Christa E. Müller , Younis Baqi
发明人： Christa E. Müller , Younis Baqi
IPC分类号： A61K31/53 , C07C50/20 , A61K31/136 , C07D251/42 , C07D239/42 , A61K31/505 , A61P9/10 , A61P9/00
CPC分类号： C07C309/53 , C07C229/74 , C07C309/46 , C07C323/37 , C07C2603/24 , C07D251/42 , C07D251/44 , C07D251/46 , C07D251/50
摘要： The present invention relates to novel P2Y12 receptor antagonists useful for treating, alleviating and/or preventing diseases and disorders related to P2Y12 receptor function as well as pharmaceutical compositions comprising such compounds and methods for preparing such compounds. The present invention is further directed to the use of these compounds, alone or in combination with other therapeutic agents, for the alleviation, prevention and/or treatment of diseases and disorders, especially the use as antithrombotic agents for inhibiting platelet aggregation.
摘要翻译： 本发明涉及可用于治疗，减轻和/或预防与P2Y12受体功能相关的疾病和病症的新型P2Y12受体拮抗剂以及包含这些化合物的药物组合物和制备这些化合物的方法。 本发明还涉及这些化合物单独或与其它治疗剂组合用于减轻，预防和/或治疗疾病和病症，特别是用作抗血栓形成剂用于抑制血小板聚集的用途。
-
公开(公告)号：US20130059899A1
公开(公告)日：2013-03-07
申请号：US13407512
申请日：2012-02-28
申请人： Evi Kostenis , Andreas Spinrath , Stephanie Hennen , Lucas Peters , Christa E. Müller , Rhalid Akkari , Younis Baqi , Kirsten Ritter
发明人： Evi Kostenis , Andreas Spinrath , Stephanie Hennen , Lucas Peters , Christa E. Müller , Rhalid Akkari , Younis Baqi , Kirsten Ritter
IPC分类号： A61K31/405 , G01N33/567 , G01N21/75 , A61P9/00 , C07D405/10 , C07D409/10 , A61P9/10 , A61P25/00 , C12Q1/02 , C07D209/42
CPC分类号： C07D209/42 , A61K31/405 , C07D405/04 , C07D409/04 , C07K14/723 , C12Q1/025 , G01N33/5041 , G01N33/566 , G01N33/6896 , G01N33/74 , G01N2333/4719 , G01N2500/00 , G01N2800/285 , G01N2800/2871
摘要： The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.
摘要翻译： 本发明涉及测定化合物改变GPR17的生物学活性的能力的方法。 所述方法尤其包括在合适量的式I的GPR17激动剂存在下使测试化合物与GPR17或功能性GPR17片段接触的步骤。
-
公开(公告)号：US20100204182A1
公开(公告)日：2010-08-12
申请号：US12227560
申请日：2007-05-24
IPC分类号： A61K31/675 , C07F9/02 , C12Q1/66 , C07D239/02 , A61K31/506 , A61P27/02 , A61P11/00 , A61P29/00 , A61P37/00 , A61P1/00 , A61P35/00 , A61P25/00 , A61P13/12
摘要： The present invention provides ectonucleotidase inhibitors represented by the following formula, including ecto-nucleotide triphosphate diphosphohydrolase (NTPDase) inhibitors and ecto-5′-nucleotidase (ecto-5′-NT) inhibitors, namely nucleotide mimetics as selective NTPDase or ecto-5′-NT inhibitors. It also provides methods for preparations of said compounds. Furthermore provided are pharmaceutical and diagnostic compositions comprising said compounds, and the use of said compounds in a medicament for treating diseases associated with ectonucleotidase activity and/or P1 or P2 receptors.
摘要翻译： 本发明提供由下式表示的外切核苷酸酶抑制剂，包括外源核苷酸三磷酸二磷酸水解酶（NTPDase）抑制剂和ecto-5'-核苷酸酶（ecto-5'-NT）抑制剂，即核苷酸模拟物作为选择性NTPDase或ecto-5' -NT抑制剂。 它还提供了所述化合物的制备方法。 此外提供了包含所述化合物的药物和诊断组合物，以及所述化合物在用于治疗与外源核苷酸酶活性相关的疾病和/或P1或P2受体的药物中的用途。
-
公开(公告)号：US08044061B2
公开(公告)日：2011-10-25
申请号：US11963477
申请日：2007-12-21
IPC分类号： C07D473/06 , C07D473/04 , A61K31/522 , A61P25/26 , A61P25/06
CPC分类号： C07D473/06 , C07D473/04
摘要： Disclosed are novel compounds of the general formula (Ia), and pharmaceutically acceptable salts, isomers, diastereomers or enantiomers thereof and their use as medicines, for example in the treatment of dopamine-related movement disorders.
摘要翻译： 公开了通式（Ia）的新化合物及其药学上可接受的盐，异构体，非对映异构体或其对映体及其作为药物的用途，例如用于治疗多巴胺相关的运动障碍。
-
-
-
搜索结果
4 条记录 (耗时 0.015 秒)
